Physician profile
Yer Vang
NPI 1699268656
$2,547.15
in general payments reported to CMS, 2019-2025
24 companies · $757 in 2025
The $757 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $74.22 · 2023: $530 · 2024: $993 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,280.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $523.64 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $404.37 | 2024-2025 | Krystexxa |
| Abbvie INC. | $275.05 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $159.29 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $150.34 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $140.78 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $137.32 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $98.91 | 2025 | Korlym |
| Lundbeck LLC | $97.20 | 2023-2025 | Rexulti |
| Horizon Therapeutics Plc | $78.68 | 2021-2022 | |
| Glaxosmithkline, LLC. | $76.77 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $70.55 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $52.29 | 2021-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $45.61 | 2023 | Gvoke Hypopen |
| Aimmune Therapeutics, INC. | $40.03 | 2024-2025 | Zenpep |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.21 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $38.12 | 2023 | |
| Janssen Pharmaceuticals, INC | $21.12 | 2025 | Spravato |
| Viiv Healthcare Company | $17.63 | 2024 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $17.44 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.32 | 2025 | Xifaxan |
| Abbott Laboratories | $16.26 | 2023 | Freestyle Libre 2 |
| Hologic Sales and Service, LLC | $15.52 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.70 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yer Vang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.